Abstract
Background
There remains a paucity of data regarding the use of potentially inappropriate medications (PIMs) in the supportive management of older adults undergoing chemotherapy. Raising awareness among healthcare providers regarding the frequency of their use and potential toxicities may help to minimize the risks to patients.
Objective
The aim of this study was to evaluate the frequency of six specific classes of medications considered PIMs by the American Geriatrics Society Beers Criteria that are commonly included in the National Comprehensive Cancer Network (NCCN) chemotherapy order templates for hematologic malignancies. The six PIMs evaluated are first-generation antihistamines, benzodiazepines, corticosteroids, H2-receptor antagonists, metoclopramide, and antipsychotics.
Methods
A total of 311 unique chemotherapy order templates published online by the NCCN for the treatment of hematologic malignancies were reviewed to determine the frequency that these six specific PIMs were recommended for supportive care.
Results
Approximately 45% of the NCCN chemotherapy templates for hematologic malignancies specifically recommended the use of at least one of the six PIMs examined. The remainder of the templates evaluated referred exclusively to the NCCN Guidelines® on Oncology for Antiemesis, which also included the use of at least one of the six PIMs evaluated.
Conclusions
These findings demonstrate that PIMs are frequently used as supportive therapy in the treatment of hematologic malignancies. Increasing healthcare provider awareness of their potential side effects may minimize the risks associated with their use in older adults with hematologic malignancies undergoing chemotherapy.
Similar content being viewed by others
References
National Cancer Institute. SEER Stat fact sheets: all cancer sites. http://seer.cancer.gov/statfacts/html/all.html.
He W, Goodkind D, Kowal P. U.S. Census Bureau, International Population Reports, P95/16-1, An Aging World: 2015; Washington, DC: US Government Publishing Office; 2016. p. 95.
Hurria A, Levit LA, Dale W, et al. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. J Clin Oncol. 2015;33(32):3826–33.
Hurria A, Naylor M, Cohen HJ. Improving the quality of cancer care in an aging population: recommendations from an IOM report. JAMA. 2013;310(17):1795–6.
Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy: a systematic review. Leuk Res. 2014;38(3):275–83.
Klepin HD, Tooze JA, Pardee TS, et al. Effect of intensive chemotherapy on physical, cognitive, and emotional health of older adults with acute myeloid leukemia. J Am Geriatr Soc. 2016;64(10):1988–95.
Deschler B, Platzbecker U, Germing U, et al. Arrangement of parameters of a geriatric and quality of life assessment in elderly patients with myelodysplastic syndromes and acute myeloid leukemia during six months of different therapeutic modalities. Haematologica. 2010;95(109):abstract no. 0464.
Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43(5):604–15.
American Geriatrics Society. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.
National Comprehensive Cancer Network. http://www.nccn.org/.
NCCN Chemotherapy Order Templates (NCCN Guidelines®) © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. To view the most recent and complete version of the guidelines, go online to http://www.nccn.org. Accessed 20 Feb 2017.
Ettinger DS, Berger MJ, Aston J, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis Version 2.2015. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. To view the most recent and complete version of the guidelines, go online to http://www.nccn.org. Accessed 20 Feb 2017.
Dotan E, Walter LC, Baumgartner J, et al. NCCN Clinical Practice Guideline in Oncology (NCCN Guidelines®) for Older Adult Oncology V.2.2015. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. To view the most recent and complete version of the guidelines, go online to http://www.nccn.org. Accessed 20 Feb 2017.
Chapell R, Aapro MS. Efficacy of aprepitant among patients aged 65 and over receiving moderately to highly emetogenic chemotherapy: a meta-analysis of unpublished data from previously published studies. J Geriatr Oncol. 2013;4(1):78–83.
Rapoport BL. Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region. Curr Med Res Opin. 2014;30(9):1875–81.
Motohashi S, Mino Y, Hori K, et al. Interindividual variations in aprepitant plasma pharmacokinetics in cancer patients receiving cisplatin-based chemotherapy for the first time. Biol Pharm Bull. 2013;36(4):676–81.
Simons KJ, Watson WT, Martin TJ, et al. Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. J Clin Pharmacol. 1990;30(7):665–71.
Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–33.
Agostini JV, Leo-Summers LS, Inouye SK. Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients. Arch Intern Med. 2001;161(17):2091–7.
Finkle WD, Adams JL, Greenland S, et al. Increased risk of serious injury following an initial prescription for diphenhydramine. Ann Allergy Asthma Immunol. 2002;89(3):244–50.
Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.
Glass JR, Sproule BA, Herrmann N, et al. Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. J Clin Psychopharmacol. 2003;23(3):260–8.
Grimes JD, Hassan MN, Preston DN. Adverse neurologic effects of metoclopramide. Can Med Assoc J. 1982;126(1):23–5.
Ganzini L, Casey DE, Hoffman WF, et al. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993;153(12):1469–75.
Neutel CI, Hirdes JP, Maxwell CJ, et al. New evidence on benzodiazepine use and falls: the time factor. Age Ageing. 1996;25(4):273–8.
Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007;5(3):263–303.
Herings RM, Stricker BH, deBoer A, et al. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med. 1995;155(16):1801–7.
Tamblyn R, Abrahamowicz M, du Berger R, et al. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc. 2005;53(2):233–41.
Sahlberg M, Holm E, Gislason GH, et al. Association of selected antipsychotic agents with major adverse cardiovascular events and noncardiovascular mortality in elderly persons. J Am Heart Assoc. 2015;4(9):e001666.
Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438–45.
Chatterjee S, Chen H, Johnson ML, et al. Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study. Am J Geriatr Pharmacother. 2012;10(2):83–94.
Fraser LA, Liu K, Naylor KL, et al. Falls and fractures with atypical antipsychotic medication use: a population-based cohort study. JAMA Intern Med. 2015;175(3):450–2.
Moore AR, O’Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15–28.
Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81(10):1361–7.
Judd LL, Schettler PJ, Brown ES, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry. 2014;171(10):1045–51.
Cantu TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med. 1991;114(12):1027–34.
Tawadrous D, Dixon S, Shariff SZ, et al. Altered mental status in older adults with histamine2-receptor antagonists: a population-based study. Eur J Intern Med. 2014;25(8):701–9.
Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65.
Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–86.
Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: a review. Ann Oncol. 1991;2(2):107–14.
Doherty KM. Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs. 1999;3(3):113–9.
Jakobsen JN, Herrstedt J. Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients. Crit Rev Oncol Hematol. 2009;71(3):214–21.
Acknowledgements
The contents of this study are solely the responsibility of the authors and do not necessarily represent the official view of the NCI, NCATS or NIH.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This publication was made possible by grant number 1K12CA167540 through the National Cancer Institute (NCI) at the National Institutes of Health (NIH), and grant number UL1TR000448 through the Clinical and Translational Science Award (CTSA) program of the National Center for Advancing Translational Sciences (NCATS) at the NIH.
Conflict of interest
Tanya Wildes receives research funding from Janssen and has consulted for Carevive Systems. Arti Hurria is a principal investigator for Celgene and Novartis, and a consultant for Boehringer Ingelheim Pharmaceuticals and Pieran Biosciences. Amy Zhou, Holly Holmes, Arti Hurria and Tanya Wildes declare that they have no conflicts of interest directly relevant to the content of this study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Zhou, A., Holmes, H.M., Hurria, A. et al. An Analysis of the Inclusion of Medications Considered Potentially Inappropriate in Older Adults in Chemotherapy Templates for Hematologic Malignancies: One Recommendation for All?. Drugs Aging 35, 459–465 (2018). https://doi.org/10.1007/s40266-018-0538-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40266-018-0538-2